These Nifty 50 stocks which have recently reported their Q3FY25 results have met or beat street estimates and stocks have surged based on the results. In this article, we will look at Automotive and Pharmaceutical companies which are among the Nifty 50 stocks and with good fundamentals.
TVS Motor Company
Price Movement
In Tuesday’s trading session, TVS Motor Company Ltd’s share price touched a day’s high of Rs. 2,368, which was up by 6.12 percent. The share price reiterated from the day’s high and was trading at Rs. 2,357.45, which is 5.65 percent higher than the previous closing price of Rs. 2,231.40.
TVS Motor Q3FY25 Financial Performance
Their Q3FY25 results show revenue from operations of Rs. 11,134.63 crore which increased by 10.09 percent year on year, from Rs. 10,113.94 crore in Q3FY24 and a 1.47 percent fall from Rs. 11,301.68 crore in Q2FY25. Their net profit increased by 19.57 percent year on year, from Rs. 509.61 crores in Q3FY24 to Rs. 609.35 crores in Q3FY25. Quarterly, the profits were up by 3.60 percent from Rs. 588.13 crore. Further,the board of directors approved a merger of Sundaram Auto Components with TVS Motor Company.
Revenue Segment
The company earned around 83.15 percent from Automotive Vehicles & Parts, 1.98 percent from Automotive Components, and the remaining 14.86 percent from Others as of the December 2024 quarter.
Cipla
Price Movement
In Tuesday’s trading session, the share price touched a day’s high of Rs. 1,473, which was up by 5.5 percent. The share price reiterated from the day’s high and was trading at Rs. 1,450.40, which is 3.89 percent higher than the previous closing price of Rs. 1,396.10.
Cipla Q3FY25 Financial Performance
Their Q3FY25 results show revenue from operations of Rs. 6,961.60 crore which increased by 7.00 percent year on year, from Rs. 6,505.66 crore in Q3FY24 and a quarterly growth remained flat from Rs. 6,961.22 crore in Q2FY25. Their net profit increased by 47.37 percent year on year, from Rs. 1,068.41 crores in Q3FY24 to Rs. 1,574.59 crores in Q3FY25. Quarterly, the profits were up by 20.65 percent from Rs. 1,305.01 crore.
Revenue Segment
The company earned 95.20 percent from the Pharmaceuticals segment and the remaining 4.8 percent from New Ventues as of the December 2024 quarter.
Written by Santhosh S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
